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Abstract
Background: The global outbreak of a novel swine-origin strain of the 2009 H1N1 influenza A virus and the
sudden, worldwide increase in oseltamivir-resistant H1N1 influenza A viruses highlight the urgent need for novel
antiviral therapy.
Methods: Here, we investigated the antiviral efficacy of poly-gamma glutamate (γ-PGA), a safe and edible biomaterial
that is naturally synthesized by Bacillus subtilis, against A/Puerto Rico/8/1934 (PR8) and A/California/04/2009 (CA04)
H1N1 influenza A virus infections in C57BL/6 mice.
Results: Intranasal administration of γ-PGA for 5 days post-infection improved survival, increased production of antiviral
cytokines including interferon-beta (IFN-β) and interleukin-12 (IL-12), and enhanced activation of natural killer (NK) cells
and influenza antigen-specific cytotoxic T lymphocytes (CTL) activity.
Conclusions: These results suggest that γ-PGA protects mice against H1N1 influenza A virus by enhancing antiviral
immune responses.
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Background
Influenza A virus is an important human pathogen
that continues to affect global health and cause pan-
demics sporadically, including the 2009 H1N1 influ-
enza outbreak. Vaccination is the most economic and
effective strategy to control influenza pandemics.
However, because influenza vaccines target the virus’s
surface antigen, they do not provide effective protec-
tion against influenza virus strains having variant an-
tigens. Moreover, current anti-influenza drugs have
several limitations and recent studies show that some
human isolates of influenza A virus (H1N1) are resistant
to antiviral drugs [1–3]. Because we cannot presage which
influenza strain will cause the next epidemic or pandemic
to ensure that vaccines target the most troublesome strain,
we need to develop antiviral drugs that broadly control in-
fluenza by enhancing effective host immune responses.
During infection, viruses begin counteracting the
host immune response comprising not only the innate
but also the adaptive immune systems. For instance,
infection of influenza virus blocks many features of
antigen-presenting cells (APCs) such as dendritic cells
(DCs) and macrophages, including production of the
antiviral cytokine type I IFN [4]. Moreover, influenza
virus-infected DCs fail to maturate costimulatory mol-
ecules and upregulate MHC class II molecules that
are pivotal for antigen-specific, T-cell activation [5].
García-Satre et al. suggested that such modulation of
the host immune response is a major mechanism
whereby viruses create a favorable environment for
their replication and persistence [6]. The hypothesis
that prophylactic immunomodulators can be used to
decrease influenza virus-induced mortality has been
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tested: The results suggest that immunomodulators,
including CpG-oligonucleotide (CpG-ODN), can in-
deed initiate a rapid immune response characterized
by antiviral and inflammatory cytokine production
[7–9]. In fact, CpG-ODN have such strong immunos-
timulatory properties that pre-treatment with a single
CpG-ODN dose of 1.5 or 2.5 μg provides partial pro-
tection to mice against lethal seasonal influenza virus.
Unfortunately, potent immunomodulator action is often
correlated with increased toxicity. However, the immuno-
modulator poly-gamma glutamate (γ-PGA), which is pro-
duced by Bacillus subtilis chungkookjang, isolated from
Chungkookjang, a traditional Korean fermented soybean
food, is safe and edible [10]. Unlike other pathogen-
associated molecular patterns, γ-PGA retains its water-
soluble, biodegradable, and non-toxic properties [11, 12].
Previously, we identified this molecule as a potent inducer
of the host immune response in in vivo tumor models [13,
14]. Recently, treatment with γ-PGA enhanced the type I
interferon and protected them against highly pathogenic
influenza A virus (H5N2) in the B6.A2G-Mx1 mouse
model [15]. A biodegradable nanoparticles also have been
demonstrated to be excellent immune stimulators with
the potential to protect against viral infections [16]. Taken
together, these investigations suggest that γ-PGA may be
effective therapy for tumor and infectious diseases. On the
basis of these results, we hypothesized that γ-PGA might
be effective as an antiviral agent against influenza virus.
Because influenza viruses enter through a mucosal sur-
face, preventing infection at the viral entry site by inducing
mucosal immunity via intranasal immunization is an at-
tractive strategy for influenza protection. In this study, we
intranasally administered γ-PGA to C57BL/6 mice in an at-
tempt to protect them from lung pathogenicity during in-
fection with lethal doses of PR8 or CA04 H1N1 influenza
A virus, strains known to induce severe immune pathogen-
icity, cause high mortality, and localize to pulmonary tissue
in mice. We found that γ-PGA-treated mice had reduced
mortality and pathogenicity during influenza infection.
Moreover, intranasal administration of γ-PGA was found
to effectively induce protective innate and CTL immune
responses against both viruses. These findings suggest that
γ-PGA may be an effective novel immunomodulator
against influenza virus-induced pulmonary pathogenicity.
Results
γ-PGA induces antiviral activity against influenza A virus
infection
To understand the therapeutic potential of immunomodu-
lator treatment against influenza virus, we investigated the
survival rate of mice after infection. We found that 50 % of
the mice infected with PR8 alone were marked within 8 or
9 days of infection. In contrast, mice administered intrana-
sal γ-PGA or CpG-ODN survived 14 days after PR8 virus
infection, with only a slight loss of body weight (Fig. 1a).
As shown in Fig. 1b, the survival rate of CA04-infected
mice treated with γ-PGA administration (100 % survival)
was higher than that of those treated with CpG-ODN
(60 % survival). These results indicate that γ-PGA induced
potent antiviral activity against influenza virus infection.
γ-PGA induces viral clearance in mice with lethal
influenza virus infection
To assess the immunomodulators’ effects on pulmon-
ary pathology in response to influenza virus infection,
we determined the virus titers in the lungs of
influenza-infected mice. At 5 dpi, a difference in the
viral load in the lung could be observed between γ-
PGA- and CpG-ODN-treated mice infected with ei-
ther virus (Fig. 2a and b). Compared to PBS treat-
ment, γ-PGA significantly decreased virus titers in the
lungs of CA04 virus-infected mice, whereas no signifi-
cant difference in viral load was observed between
CpG-ODN- and PBS-treated mice infected with either
virus. Compared to PBS-treated controls, γ-PGA- and
CpG-ODN-treated mice each had significantly lower
viral loads in the lung at 7 dpi (p < 0.01, p < 0.05, re-
spectively; Fig. 2a and b).
Next, we evaluated the extent of the pathologic changes
in the lungs of influenza virus-infected mice treated with
immunomodulators. Typically, influenza A virus replica-
tion is accompanied by infiltration of immune cells in the
lung tissue of the infected host [9]. Consistent with pub-
lished data, we observed induction of widespread inflam-
matory processes in influenza virus-infected mice not
treated with immunomodulators. As expected, no histo-
logic alterations indicative of severe inflammation or dis-
ruption of the membrane barrier were observed in the
lung tissue of virus-infected mice given γ-PGA (Fig. 2c).
Furthermore, only mild histopathologic changes were de-
tected in the lungs of a PR8-infected mouse given CpG-
ODN. However, lungs of CA04 virus-infected mice given
CpG-ODN had considerably more bronchial cell infiltrates
and peribronchial inflammation. Collectively, these results
show that intranasal administration of γ-PGA could pre-
vent histopathologic alterations in the lungs and protect
mice against lethal influenza virus infection.
γ-PGA enhances activation of innate immune cells in
influenza-infected mice
In the early phase of influenza virus infection, host im-
mune responses include inflammatory cytokines, with im-
mune cells such as NK cells and DCs playing a critical role
in host defense [17, 18]. Norton et al. suggest that immu-
nomodulators such as CpG-ODN and cholera toxin
strongly protect against viral infections by promoting the
innate immune response [9]. We, therefore, examined
whether γ-PGA alters immune cell activation in the lungs
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during influenza virus infection. As expected, cytotoxicity
activity in purified lung NK cells from either γ-PGA- or
CpG-ODN-treated mice was approximately 2.5-fold higher
than that of cells from untreated mice (Fig. 3a).
Next, we assessed γ-PGA’s ability to induce maturation
of DCs in influenza virus-infected mice by using FACS
analysis to measure the expression of maturation marker
CD86 in lung DCs. Both γ-PGA- and CpG-ODN-treated
mice had higher CD86 expression than untreated mice
did (Fig. 3b). In addition, we confirmed that other DC
maturation markers such as CD40 and CD80 are
expressed in higher amounts in lung DCs from γ-PGA-
treated mice than in those from untreated mice (data
not shown). Taken together, these results show that in-
tranasal γ-PGA promotes an innate immune response in
the lung after activating NK cells’ cytotoxicity and DCs’
maturation during influenza virus infection.
γ-PGA induces cytokine production in mice infected with
influenza virus
Because cytokines trigger innate and adaptive immune re-
sponses, including APC maturation and induction of cyto-
toxic NK cells and CTLs, they can protect against virus
infection [19, 20]. Österlund et al. suggest that the pan-
demic 2009 H1N1 influenza virus induces a weak innate
immune response, producing only small amounts of
antiviral and inflammatory cytokines, particularly IFN-α,
IFN-β, and TNF-α [21]. To determine whether γ-PGA af-
fects cytokine production during influenza virus infection,
we examined the amount of cytokines in lung homoge-
nates by using ELISA. Consistent with previous results [7],
CpG-ODN induced increased cytokine production in lung
homogenates during influenza virus infection (Fig. 4).
TNF-α, RANTES, IL-12, and IFN-β production levels
were significantly higher in γ-PGA-treated mice than in
untreated mice (Fig. 4). Therefore, γ-PGA also induced in-
creased cytokine production in lung homogenates during
influenza virus infection.
γ-PGA promotes influenza virus-specific CTL activity in
mice infected with influenza virus
Influenza virus-specific, CD8+ T cell-mediated immunity
is a critical component of the host response after infec-
tion with H5N1, H3N2, or H1N1 virus strains [22, 23].
The capacity of CD8+ T cells to produce multiple ef-
fector cytokines such as IFN-β and TNF-α has also
emerged as a positive correlate of effective CTL immun-
ity after virus infection [24], suggesting that CD8+ T cells
contribute to the primary mechanism of virus clearance.
To determine whether γ-PGA elicits effective,
influenza-specific CTL activity, mice were treated
with γ-PGA for 7 days after infection with either
Fig. 1 γ-PGA protects mice after a lethal dose of influenza A virus. C57BL/6 mice (n = 10 per group) were intranasally inoculated with 1 MLD50 of
either (a) PR8 or (b) CA04 viruses. Mice were given either intranasal CpG-ODN 24 h prior to virus infection or intranasal γ-PGA 24 h post- inoculation
(hpi). Body weight and survival were monitored daily for 14 days
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CA04 or PR8 virus. On day 9, the cytotoxic activity
of lung CD8+ T cells was assayed. As shown in Fig. 5a
and b, lung CD8+ T cells from γ-PGA-treated mice
had high levels of CTL activity against both influenza
viruses. In addition, the influenza-specificity of the
IFN-γ-expressing CD8+ T cell response was observed
after stimulation with either UV-inactivated CA04 or
PR8 virus. Consistent with the CTL activity results,
the number of CD8+/IFN-γ-secreting cells was signifi-
cantly higher in γ-PGA treated-mice than in untreated
mice (Fig. 5c and d), with CpG-ODN inducing responses
similar to those induced by γ-PGA. Taken together, our
data clearly show that γ-PGA plays a crucial role in indu-
cing the anti-influenza cytotoxic activity of CD8+ T cells
in the lung.
The antiviral effects of γ-PGA are dependent on CD8+ T
cells in CD4+ or CD8+ T cell depleted mice models
CD4+ and CD8+ T cells are both reported to play
roles in clearing primary influenza virus infections
[25]. Eichelberger et al. found that mice depleted of
CD8+ T cells cleared virus similarly to normal mice
[26], casting some doubt on the relative importance
of CD8+ T cells in host defense against viral infec-
tions. To confirm which subsets of T lymphocytes are
important for protection against lethal CA04 virus in-
fection, we performed in vivo antibody depletion ex-
periments. As shown in Fig. 6, preventive antiviral
effects were abrogated through CD8+ and CD4+ plus
CD8+ T cell depletion in the γ-PGA-treated mice.
Body weight loss of the mice in these two groups was
greater than that in mice in the isotype control group
(Fig. 6a), and none of the mice survived (Fig. 6b). De-
pletion of CD4+ T cells also decreased the level of
protection in γ-PGA-treated mice but not to the same
degree as that seen with CD8+ T cell depletion
(Fig. 6b). In addition, γ-PGA-treated mice that re-
ceived isotype control antibody injections also suf-
fered weight loss; but, they recovered rapidly after
day 9, and all the mice survived (Fig. 6). These results
indicate that CD8+ T cells were essential for the anti-
influenza effect generated by γ-PGA.
Discussion
The emergence of highly contagious influenza virus
strains, such as the new pandemic H1N1 influenza,
Fig. 2 γ-PGA reduces the viral load and inflammation in mouse lung during influenza A virus infection. C57BL/6 mice (n = 5 per group) were
intranasally inoculated with 1 MLD50 of either PR8 or CA04 viruses. Mice were given either intranasal CpG-ODN 24 h prior to virus inoculation or
intranasal γ-PGA 24 h after infection. Mice were killed at 3, 5 or 7 days post-inoculation (dpi), and their lungs were collected for virus titer and
histologic analyses. Titers of (a) PR8 and (b) CA04 viruses in the lung were measured at 5, 7, and 9 dpi. c H&E-stained, formalin-fixed lung samples
of mice with or without immunomodulator treatment; PBS-only and virus-only negative controls are shown for comparison. Representative sections
are shown (magnification, ×100). † indicates p < 0.01 compared to the control group; * p < 0.05 relative to the control group
Kim et al. Virology Journal  (2015) 12:160 Page 4 of 10
represents a serious threat to global human health,
and influenza virus vaccines do not protect against
antigenically drifted strains that frequently appear to
cause seasonal influenza outbreaks. Given the emer-
gence of drug-resistant strains and limited protection
capability, a great need exists to develop strategies to
protect against the next pandemic influenza. The
current study evaluated the antiviral efficacy of intra-
nasal administration of γ-PGA to prevent lethality in
mice infected with H1N1 influenza A viruses.
Fig. 3 γ-PGA promotes NK cells’ cytotoxicity and enhances DCs’ maturation in influenza virus-infected mice. C57BL/6 mice (n = 5) were infected
with PR8 and CA04 influenza viruses at 1 LD50 per mouse. After 24 h, mice were intranasally administrated with 100 μg of γ-PGA and 5 μg of
CpG-ODN administrated prior to virus infection for 24 h. a Lung cell suspensions were magnetically separated to purify NK cells by positive selection
using the CD49b antibody. Purified NK cells were mixed with target cells at an effector cell to target cell ratio of 50:1, and specific lysis values were
quantified by performing lactate dehydrogenase release assays. b Cell suspensions were stained with anti-mouse CD86 antibody. To avoid nonspecific
counting, cells were gated with anti-mouse CD11c + antibody and then DCs’ maturation was measured by flow cytometry. In each overlay, unfilled
histograms represent the expression of maturation marker on lung DCs. Data are representative of two independent experiments
Fig. 4 . γ-PGA induces cytokine production in mice infected with influenza virus. C57BL/6 mice (n = 5) were infected with PR8 and CA04 influenza
viruses at 1 LD50 per mouse. After 24 h, mice were intranasally administrated with 100 μg of γ-PGA and 5 μg of CpG-ODN administrated prior to
virus infection for 24 h. Two days later, mice sacrificed and lung tissue homogenized. Cytokine production in lung homogenates of (a) PR8 and (b)
CA04 virus infected mice was analyzed: TNF-α, RANTES, IFN-β and IL-12 by ELISA. Data are representative of two independent experiments. † indicates
p < 0.01 compared to the virus infection group; * p < 0.05 relative to the virus infection group
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Norton et al. reported that intranasal immunomodula-
tors induce a local immune response that results in de-
creased mortality upon influenza A virus infection [9].
In the present study, we showed that intranasal adminis-
tration of γ-PGA shortly after viral infection could in-
hibit influenza virus replication, leading to a significant
reduction in pulmonary viral titers and an improved
survival rate of infected mice. Recently, Okamoto et al.
reported that intranasal vaccination with γ-PGA nano-
particles containing influenza HA protein enhances pro-
tection against influenza virus infection [27]. Taken
together, although therapeutic evaluation in humans is
required, these findings indicate a therapeutic utility for
γ-PGA when used as an anti-influenza virus drug.
Fig. 5 γ-PGA promotes influenza-specific CTL activity in mice with infected influenza virus. C57BL/6 mice (n = 5) were infected with PR8 and CA04
influenza viruses at 1 LD50 per mouse. After 24 h, mice were intranasally administrated with 100 μg of γ-PGA and 5 μg of CpG-ODN administrated
prior to virus infection for 24 h. Nine days after infection, purified CD8+ T cells isolated from single-cell, lung suspensions of (a) PR8 and (b) CA04
virus infected mice were used as follows. To determine CTL activity, purified CD8+ T cells were mixed with target cells at an effector cell to target
cell ratio of 50:1, and specific lysis values were quantified by performing lactate dehydrogenase release assays. For the ELISPOT assay, purified CD8+ T
cells of (c) PR8 and (d) CA04 infected mice were stimulated with UV-inactivated influenza viruses and incubated for 72 h. Data are representative of
two independent experiments with four to five replicate wells per group. Bars signify that test groups were significantly different from virus-alone
groups when analyzed by t-test († indicates p < 0.01 compared to the virus infection group; *, p < 0.05 relative to the virus infection group)
Fig. 6 The depletion of CD8+ T cells eliminates the antiviral effect of γ-PGA against influenza A virus infection. Anti-CD4 (GK1.5), anti-CD8 (53.6.72), and
isotype control antibodies were injected into mice before and after challenge. a Body weight loss and (b) survival were monitored for 14 days
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To develop optimal drugs against the influenza viruses,
it is important to understand their mechanisms of action
on the immune system [28]. Host innate immune re-
sponse is the first line of protection against infection by
viruses and is essential in local control of invading mi-
crobes. During influenza infection, DCs are necessary to
induce an immune response that clears the virus from
the lungs [29, 30]. In addition, influenza virus is able to
evade host immunity by attenuating NK cell lysis of in-
fluenza virus-infected cells [30, 31]. Österlund et al. re-
ported that pandemic H1N1 (A/Finland/553/09) virus
and seasonal H1N1 virus (A/Brisbane/59/07) induce a
relatively weak innate immune response in macrophages
and DCs, as evidenced by a poor expression of antiviral
and inflammatory cytokine genes [21]. IFN-β can inhibit
the replication of a wide variety of viruses, which con-
tributes to key effector molecules of the immune re-
sponse to viruses [32]. IL-12 and RANTES are also
important cytokines involved in cellular immunity,
which can potently stimulate cytotoxic T cells as well as
NK cells’ activation [33–35]. Therefore, cytokines are
promising of antiviral drugs for enhancing the host im-
mune response against influenza virus infection. We
found that cytokine production levels and activation of
innate immune cells in lung samples from γ-PGA-
treated mice were higher than those from untreated con-
trols. In addition, we also observed a significantly higher
number of activated NK1.1+ cells in total lung cells from
γ-PGA-treated mice than in those from untreated mice
(data not shown). Thus, our findings suggest that intra-
nasal γ-PGA promotes the innate immune response dur-
ing virus infection, protecting against influenza.
Cell-mediated immune responses play a crucial role in
protecting the host from invading pathogens [36, 37].
Virus clearance requires strong Th1-polarized immune
responses characterized by IFN- γ production and CTL
responses in the systemic compartment [38]. Moreover,
earlier studies show that both CD4+ and CD8+ T cells
contribute equally to protection against pandemic H1N1
influenza virus [24, 25]. In accordance with these re-
ports, we observed that in vivo depletion of CD4+ and
CD8+ T cells completely abrogated antiviral activity in γ-
PGA-treated mice, with γ-PGA having no antiviral ef-
fects in CD8+ T cell-deficient mice. Our data clearly
showed that γ-PGA increases the cytotoxic activity of
CD8+ T cells in the lung against H1N1 influenza A vi-
ruses. Hanna et al. reported the precise contribution of
NK cells to induction of adaptive immunity during influ-
enza infection of the lung [39]. Moreover, other studies
have shown that depletion of NK1.1+ cells decreases the
induction of virus-specific CTL activity and increases in-
fluenza disease severity during influenza virus infection
in mice [40]. The major function of DCs during an anti-
viral immune response is to process and present viral
antigenic peptides in the draining lymph nodes to rare,
antigen-specific T cells [41]. Additionally, cytokines such
as IL-12 are key molecules that trigger the adaptive im-
mune responses (including of DCs maturation, differen-
tiation of Th1 and Th2 cells, and induction of cytotoxic
NK cells and CTLs), resulting in protective layers against
virus infection [42, 43]. Taken together, our results indi-
cate that γ-PGA enhances influenza-specific CD8+ T cell
immunity, increasing cytokine production and activation
of antigen-presenting cells. However, the molecular
mechanism by which γ-PGA provided complete protec-
tion against influenza virus remains unknown.
Conclusions
In our study, we confirmed that γ-PGA enhances
influenza-specific CD8+ T cell immunity, increasing
cytokine production and activation of antigen-presenting
cells. We also showed that administration of γ-PGA sig-
nificantly improved the survival rate and virus inhibition
of mice from infections of PR8 and CA04 viruses.
Although further mechanism studies are needed, we
showed that intranasal γ-PGA induced a higher
influenza-specific CTL response and innate immune re-
sponse than did CpG-ODN after influenza H1N1 virus
infection. In light of this evidence, we suggest that γ-
PGA may be a more potent immunomodulator against
H1N1 influenza A virus infection than CpG-ODN.
In summary, we report for the first time that intranasal
administration of γ-PGA generated significant antiviral
activity in H1N1 influenza A virus-infected mice. These
novel findings indicate that γ-PGA mediates anti-viral
immunity via the induction of antigen-specific CTL ac-
tivity, suggesting that this molecule could be a good can-
didate for development as a novel immunomodulator for
anti-influenza treatment.
Methods
Mice, cells, and viruses
Six-week-old female C57BL/6 (H-2b) mice were purchased
from KOATECH (Pyeongtaek, Korea) and housed in spe-
cific pathogen-free conditions at Korea Institute of Bio-
science and Biotechnology (KRIBB) in Daejeon, Korea.
Mouse experiments were approved by KRIBB’s Institu-
tional Review Board. The mouse lymphoma cell line EL-4
(H-2b) was obtained from the Korea Cell Line Bank
(Seoul, Korea) and maintained in complete Dulbecco’s
modified Eagle’s medium (DMEM; Hyclone; UT, USA)
supplemented with 10 % fetal bovine serum (FBS;
Hyclone). Both A/Puerto Rico/8/1934 (PR8) and A/
California/04/2009 (CA04) H1N1 influenza A viruses
were grown for 2 days at 37 °C in the allantoic cav-
ities of 10-day-old fertile chicken eggs. Virus stocks
were propagated in the allantoic cavity of 10-day-old,
embryonated, and specific pathogen-free hen’s eggs at
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37 °C. Clarified allantoic fluid was aliquoted and im-
mediately frozen at −80 °C.
Influenza virus infection
Mice were lightly anaesthetized and challenged intrana-
sally with 50 % of the mouse lethal dose (MLD50) of PR8
or CA04 influenza A viruses in a total volume of 30 μl.
After infection, mice were monitored daily for morbidity
(i.e., body weight loss) and survival for up to 14 days
post-infection (dpi). Individual body weights were re-
corded for each group on various dpi. The mice having
more than 20 % of body weight lost were considered to
have reached the experimental endpoint and were hu-
manely killed.
To determine the titer of infectious virus, lung samples
of 3 mice per group were collected at 3, 5, and 7 dpi.
Lung samples were homogenized in 1 ml of sterile PBS
containing penicillin G (200,000 U/ml), streptomycin
(40,000 U/ml), polymyxin B (20,000 U/ml), and gentami-
cin (5 mg/ml). The titers of clarified lung tissue homoge-
nates were determined by calculating the standard 50 %
egg infectious dose (EID50); the detection limit was
0.75 log10 EID50/ml.
Immunomodulator treatment
Because CpG-ODN has been demonstrated to be an ex-
cellent immunomodulator with the potential to protect
against influenza virus infection [7], it was used as the
positive control for our experiments to test the anti-
influenza efficacy of γ-PGA immunomodulator treat-
ment. CpG-ODN was purchased from InvivoGen (SD,
USA), and γ-PGA was kindly provided by Bioleaders
Corporation (Daejeon, Korea). Mice were infected with
either CA04 or PR8 (1 MLD50), and the immunomodu-
lators were used as follows: γ-PGA (100 μg in 20 μl
endotoxin-free PBS [Sigma; MO, USA]) was intranasally
administered to mice for 7 days starting 24 h after virus
infection or CpG-ODN (5 μg in endotoxin-free PBS)
was intranasally administered once 24 h prior to virus
infection. Control mice were administered an equal vol-
ume of endotoxin-free PBS.
Histopathology
At 5 dpi, fresh lung tissues were collected from PBS-
treated, CpG-ODN-treated, and γ-PGA-treated mice
(n = 3 per group), fixed in 10 % neutral buffered for-
malin and then dehydrated, embedded in paraffin,
and cut into 4 μm-thick sections. The sections were
stained with hematoxylin and eosin (H&E) and exam-
ined by using an Olympus TH4-200 System Micro-
scope attached to a DP72 Microscope Digital Camera.
The captured images were analyzed by using DP2-
BSW software (Ver.2.1, OLYMPUS).
Flow cytometry analysis
Single-cell suspensions were prepared from mouse lung
by using type II collagenase and DNase treatment. In
brief, whole lung tissue was removed, minced in collage-
nase digestion solution (10 ml PBS containing 20 μg/ml
type II collagenase [Roche, NJ, USA] and 100 μg/ml
DNase I [Roche]), and incubated at 37 °C for 30 min.
Lung tissue pieces were meshed through a 40-μm cell
strainer (Falcon) before red blood cells in the super-
natant were lysed by using red blood cell-lysis buffer
(Sigma). To measure the population of lung immune
cells, approximately 1 × 106 cells were stained in 100 μl
FACS buffer (PBS containing 2 % FBS [v/v] and 0.02 %
sodium azide [v/v]) with FITC-conjugated anti-mouse
CD40, CD80, and CD86 antibodies. To avoid nonspecific
counting, cells were gated with either anti-mouse
CD49b or anti-mouse CD11c+ antibody. All antibodies
were purchased from BD Biosciences (CA, USA). Data
were acquired on a BD FACSCalibur (BD Biosciences)
and analyzed by using the CELLQuest Pro software (BD
Biosciences).
Quantification of cytokines
To count cytokines, mouse lung tissue was harvested
and homogenized in 2 ml of tissue protein extraction re-
agent (Pierce: IL, USA) containing protease inhibitor
cocktail (Roche). The homogenate was centrifuged at
16,000 g for 20 min at 4 °C before the supernatant was
harvested. The amounts of the following cytokines were
analyzed: IL-1β, IL-4, IL-6, IL-12p40, IL-15, IFN-γ,
tumor necrosis factor-α (TNF-α), and regulated on acti-
vation normal T-cell expressed and secreted (RANTES).
The concentration of IFN-β in the homogenate was deter-
mined by using an IFN-β ELISA kit (PBL Laboratories;
NJ, USA).
Cytotoxicity assay
To isolate the CD8+ T cells and NK cells, total lung cells
were first digested in collagenase digestion solution.
Both cell types were magnetically separated via negative
selection with a CD8+ T-cell isolation kit (Miltenyi Bio-
tec; CA, USA) and positive selection with a CD49b
(DX5) kit (Miltenyi Biotec). The cell-mediated cytotox-
icity assay was performed using the EL-4 cells as target
cells [44] and quantified by using the lactate dehydro-
genase (LDH)-release assay kit according to the instruc-
tions (Promega; CA, USA). In brief, lung NK cells and
CD8+ T cells were mixed with target cells at an effector
cell to target cell ratio of 50:1 and incubated at 37 °C for
4 h. To determine the CD8+ T cells’ cytotoxicity, target
cells were stimulated with the 50 % tissue culture-
infective dose (TCID50) of UV-inactivated virus for 24 h.
Each sample was incubated with 50 μl of substrate at
room temperature for 30 min, and optical density (OD)
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values were measured at 490 nm wavelength by using
the VICTOR3 1420 multilabel counter plate reader
(Perkin-Elmer; MA, USA). The cytotoxicity percent-
age was calculated by using the following formula:
(mean experimental OD value–mean spontaneous OD
value)/(mean maximal OD value–mean spontaneous
OD value) × 100.
IFN-γ ELISPOT assay
Ninety-six-well filtration plates (Millipore, MA, USA) were
pre-coated with anti-mouse IFN-γ antibody (5 μg/ml; BD
Biosciences) overnight at 4 °C. After the plates were
washed four times with PBS and then blocked with RPMI
1640 medium (Gibco), CD8+ T cells (1 × 105 cells in 100 μl
of medium) were added to each well of the filtration plates
along with UV-inactivated influenza virus (1 TCID50) [45]
in 100 μl of medium). The plates were incubated for 72 h,
washed with PBS containing 0.5 % Tween-20 (PBS-T), and
incubated with biotin-conjugated anti-mouse IFN-γ anti-
body (1 μg/ml) for 2 h at room temperature. After 5
washes with PBS-T, diluted horseradish peroxidase (HRP)-
conjugated streptavidin antibody (1:200; BD Biosciences)
was added to the each well and incubated at room
temperature for 1 h. The cells were washed 5 times with
PBS-T; ELISPOT AEC substrate (100 μl; BD Biosciences)
was added to develop the reaction, and then the reaction
was stopped by washing the cells with double-distilled
water. The spots were counted automatically by using the
ELISPOT CTL-ImmunoSpot S5 UV Analyzer (Cellular
Technology; OH, USA).
CD4+ and CD8+ T cell depletion
For T-cell depletion studies, mice were immunized with
100 μg of γ-PGA 5 days after influenza virus inoculation.
Groups of mice were then injected intraperitoneally with
100 μg anti-CD4 antibody (clone GK1.5; BioLegend),
100 μg anti-CD8 antibody (clone 53.6.72; BioLegend),
and 100 μg of both IgG2b isotype control antibodies
(BioLegend). Antibodies were injected every other day
three times before and twice at 3 days and 7 days after
inoculated with a MLD50 of CA04 virus (5.5 EID50/ml
per mouse). The positive control group was not injected
with antibodies but was γ-PGA-treated after challenge.
After virus infection, mice were monitored daily for
weight loss and survival.
Statistical analyses
The analyses were done by using GraphPad Prism ver-
sion 5.00 for Windows (GraphPad Software, CA, USA).
P values of less than 0.05 (p < 0.05) were considered to
be statistically significant.
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